Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including deaths.
The decision is a stunning blow for a drug that was approved in 2019, heralded as a new way to treat the inherited blood disorder. Pfizer acquired the maker of Oxbryta, a biotech company called Global Blood Therapeutics, in 2022 for $5.4 billion.
In a statement, Pfizer said the decision to voluntarily withdraw Oxbryta was made based on data showing the drug’s benefit no longer outweighed the risks. Data suggested the drug might increase the risk of pain crises and “fatal events.”
Click this link for the original source of this article.
Author: Adam Feuerstein and Jason Mast
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
